Kornimate/medical-research-clean huggingface dataset:
endoscopic band ligation versus argon plasma coagulation for the treatment of gastric antral vascular ectasia: a randomized clinical trial

Conditions: Gastric Antral Vascular Ectasia

Summary: the investigators goal is to compare the standard argon plasma coagulation (apc) treatment with endoscopic band ligation (ebl) in patients with gastric antral vascular ectasia.

gastric antral vascular ectasia (gave) is a vascular structural malformation in the stomach that can lead to active or chronic intermittent gastrointestinal bleeding or chronic iron-deficiency anemia. the current standard endoscopic treatment is with apc. there have been multiple reports and case series in the literature about successful treatment with ebl for gave, even in cases where apc was unsuccessful for treatment of gave. our goal is to compare the standard apc treatment with ebl in patients with gastric antral vascular ectasia.

Eligibility criteria:
inclusion criteria: * consecutive patients with gave identified at endoscopic examination, patients may have active gi bleeding, chronic anemia or drop in hemoglobin levels. exclusion criteria: * patients with previous endoscopic treatment for gave within the last 3 months, patients with gave without chronic anemia or active bleeding, patients in whom another possible source of gi bleeding is found

Keywords: gastric antral vascular ectasia argon plasma coagulation endoscopic band ligation gave
yoga to reduce cancer fatigue

Conditions: Breast Neoplasm

Summary: a randomized trial from the british national health service found that supervised exercise benefits women with early stage breast cancer with improved functional and psychological benefit after a 12-week intervention and 6 months later. considering the needs of breast cancer patients and survivors and the reported benefits of exercise and yoga intervention, the investigators propose a pilot study of an 8-week yoga intervention in breast cancer patients. this study would specifically address measures of fatigue and psychosocial distress in the population of breast cancer patients during treatment and within the year following treatment. currently there is very limited literature on yoga intervention in this population.


Eligibility criteria:
inclusion criteria: * potential subjects must have had histologically or cytologically confirmed breast cancer. this includes, but is not limited to: breast cancer-in situ; ductal carcinoma in situ; lobular carcinoma in situ; cystosarcoma phyllodes; inflammatory breast carcinoma; invasive breast carcinoma; and breast cancer not otherwise specified; cancer must be stage 0 through stage iii. * treatment completion within the past calendar year. * age ≥ 18 years. while breast cancer can occur in the pediatric population, the pediatric population is best served by trials specifically designed for their age group. * life expectancy of greater than 1 year. * karnofsky ≥ 60%; see appendix a. * women of childbearing potential are eligible for this study. * pregnant women are eligible for this study pending a doctor's note. * the ability to understand and complete the study questionnaires. * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * patients with known metastasis. * patients who are actively participating in a yoga class. * known uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would compromise subject health during yoga.

Keywords: fatigue yoga anxiety quality of life
open label study to assess safety and immunogenicity of omalizumab liquid formulation.

Conditions: Asthma

Summary: the primary objective of this study is to assess the immunogenic potential of the liquid formulation of omalizumab administered over a period of 6 months in moderate to severe persistent allergic asthma patients 12 years of age or older, with no previous exposure to the drug (omalizumab naïve patients). the secondary objective of this study is to assess the safety of the liquid formulation of omalizumab in the same patients.


Eligibility criteria:
inclusion criteria: * patients 12 years old or above with moderate to severe allergic asthma * body weight greater than 30kg and less than 150 kg and total serum ige level greater than 30 to less than 700 iu/ml * diagnosis of allergic asthma greater than 1 year duration, according to the american thoracic society criteria (14) and at screening, a history consistent with clinical features of moderate to severe persistent asthma. * positive skin prick test (diameter of wheel is greater than 3mm) to at least one perennial allergen within the previous one year to visit 1, to which the patient will be exposed on a regular basis (most days) for the duration of the study. * no clinically significant asthma exacerbations that required treatment with systemic corticosteroids during the four weeks immediately prior to screening visit (visit 1) and during screening period (between visit 1 and 2) * demonstrated evidence of inadequate asthma symptom control, despite treatment with ics according to clinical features of moderate to severe persistent asthma. exclusion criteria: * previous exposure to omalizumab * previous exposure to other humanized proteins or monoclonal antibodies * known haha to other monoclonal antibodies * history of hypersensitivity to any of the study drugs or to drugs with similar chemical structures * known hypersensitivity to any ingredients, including excipients of the study medication or drugs related to omalizumab (e.g. monoclonal antibodies, polyclonal gamma globulin) * active lung disease other than allergic asthma (e.g. cystic fibrosis, bronchiectasis) * elevated serum ige levels for reasons other than allergy (e.g. parasite infections, hyperimmunoglobulin e syndrome, wiskott-aldrich syndrome or allergic bronchopulmonary aspergillosis)

Keywords: asthma omalizumab safety allergic asthma adolescents
effects of physical activity on cardiovascular risk and quality of life

Conditions: Cardiovascular Diseases; Quality of Life

Summary: community intervention trial, randomized, to promote regular pa and social and cultural support activities for 9 months in older-adult primary care users and assess their effects on cardiovascular risk factors and health-related quality of life.

a structured program to promote physical , according to the recommended guidelines and supervised by healthcare personnel should be deployed to assess their short, medium and long-term effects on cvd risk and qulity of life. the aim of this study was to evaluate the effectiveness of a program to promote physical, social and cultural activities for 9 months on cardiovascular risk factors and quality of life among older-adults,

Eligibility criteria:
inclusion criteria: \* adults users of 4 primary health care centers in catalunya. exclusion criteria: * previous episode of ischemic heart disease (\<6 months). * outbreak of arthritis with limited ability to ambulate. * lung or heart disease with dyspnea mild-moderate efforts.
prediction of coronary artery disease severity by epicardial adipose tissue thickness

Conditions: Myocardial Infarction

Summary: is to test the hypotheses that epicardial adipose tissue can be a marker of severity of coronary artery disease in myocardial infarction patients

epicardial adipose tissue is defined as the adipose tissue between the visceral pericardium and the outer margin of the myocardium which can be considered an endocrine organ that secretes pro-inflammatory and anti-inflammatory cytokines and chemokines including adiponectin.as investigators know, inflammatory response is an important factor in the coronary atherogenesis. therefore,epicardial adipose tissue is likely to be connected with the severity of coronary artery disease.recent studies showed that the thickness of the epicardial adipose tissue in patients with coronary artery disease was greater than that with normal coronary arteries. epicardial adipose tissue will be assessed using transthoracic echocardiography and cardiac magnetic resonance which allows for an accurate volumetric quantification of epicardial fat.

Eligibility criteria:
inclusion criteria 1. normal thoracic shape 2. sinus rhythm 3. without severe respiratory diseases exclusion criteria: 1. contraindication for cardiac magnetic resonance. 2. patients who previously underwent coronary artery bypass grafting or percutaneous coronary angiography prior to admission 3. history of chronic kidney disease with glomerular filtration rate \<30 ml/min 4. pericardial and/or pleural effusion.
feasibility of holmium-166 micro brachytherapy in head and neck tumors

Conditions: Radioisotopes; Head and Neck Neoplasms

Summary: the main objective is to establish the feasibility of 166-holmium microspheres for intratumoral injections in oral squamous cell carcinoma (oscc) of the tongue. participants will receive intratumoral injections with a low radioactive 166-holmium microspheres followed by surgical resection

166-holmium microspheres poly lactic acid microspheres are currently used in selective internal radiation therapy. these microspheres emits beta radiation. the majority of the radiation dose will be absorbed within 3.2 mm with a maximum penetration in tissue of 9 mm. therefore this can result in a high local tumor ablative dose with minimal dose to healthy adjacent tissue.

Eligibility criteria:
inclusion criteria: 1. patients must have given written informed consent. 2. aged 18 years and over. 3. confirmed histological diagnosis of squamous cell carcinoma of the tongue. 4. primary tumor, regional nodes, metastasis (tnm) stage t1-2 nx m0. 5. eligible for local surgery with curative intent. 6. world health organization (who) performance status 0-2. exclusion criteria: 1. previous oncologic surgery and/or external beam radiation therapy on the tongue and oral floor. 2. major surgery (oro-facial) within the past 4 weeks or incompletely healed surgical incisions before starting study therapy. 3. any unresolved toxicity greater than national cancer institute (nci), common terminology criteria for adverse events (ctcae version 4.03) grade 2 from previous anti-cancer therapy. 4. pregnancy or nursing (women of child-bearing potential). 5. patients suffering from psychic disorders that make a comprehensive judgment impossible, such as psychosis, hallucinations and/or depression. 6. previous enrolment in the present study.

Keywords: intratumoral tongue microspheres
the effect of cataract extraction on the contractility of ciliary muscle

Conditions: Presbyopia; Cataract

Summary: the purpose of this study is to investigate the changes in the pilocarpine-induced ciliary body movement before and after cataract extraction in order to determine the effect of lens sclerosis on the ciliary muscle contractility.

the functional changes in the ciliary body in presbyopia are not only important in a study of the mechanism for presbyopia but are also a key to various procedures or devices used to restore accommodation. therefore, it is becoming increasingly important to quantify the in vivo accommodative changes in the aging ciliary muscle with and without a lens. we are going to evaluate the changes in the pilocarpine-induced contractility of the ciliary muscle in eyes with presbyopia before and after cataract extraction using ultrasound biomicroscopy (ubm).ubm will be performed with and without instilling 2 % pilocarpine, as well as before and 2 months after cataract extraction. images of the ciliary body will be compared visually using adobe photoshop 7.0.

Eligibility criteria:
inclusion criteria: * age : same or more than 55 years * patients with senile cataract who are going to get cataract surgery exclusion criteria: * age : less than 55 years * previous ocular disease other than cataract.

Keywords: presbyopia
intra-coronary infusion of bone marrow derived autologous cd34+ selected cells in patients with acute myocardial infarction

Conditions: Myocardial Infarction; Coronary Artery Disease

Summary: following a heart attack the acute loss of heart muscle cells results in a cascade of events causing an immediate decrease in cardiac function that has the potential to persist long term. despite revascularization of the infarct related artery circulation and appropriate medical management to minimize the stresses on the heart walls, a significant percentage of patients experience permanent cardiac dysfunction and consequently remain at an increased life-time risk of experiencing adverse cardiac events, including death. there is a great potential for stem cell therapy, using a variety of cell precursors (particularly hematopoietic,)to contribute to new blood vessel formation (and possibly limited heart muscle formation) and muscle preservation in the myocardial infarct zone. the administration of cells via an infusion through the infarct related artery appears to be feasible and result in a clinical effect in some studies. therefore, we propose to evaluate the safety and efficacy of a cd34+ selected stem cell product (amr-001), administered through the infarct related coronary artery 6 to 9 days after successful infarct related artery stent placement. the primary objective of the study is to determine the feasibility and safety of prospectively identifying patients at risk for clinically significant cardiac dysfunction following a myocardial infarction and the ability to isolate and infuse via the affected coronary circulation an autologous bone marrow derived cd34+ cell product at four dose levels. the secondary objective of the study is to assess the effect on cardiac function and infarct region perfusion. a concurrent patient group meeting eligibility but not receiving cd34+ cells will be evaluated similar to the treated group to assess the rate of significant spontaneous improvement in cardiac function without cd34+cell infusion.


Eligibility criteria:
inclusion criteria: * age 18 - 75 years. * acute st elevation myocardial infarction meeting acc/aha criteria, with symptoms of chest pain within 3 days of admission. criteria include (st elevation \> 1mm in limb leads or 2 mm in two or more precordial leads and increased levels of troponin, cpk mb or both) * nyha heart failure class of i, ii or iii exclusion criteria: * patients who are not candidates for percutaneous intervention, conscious sedation, mri, spect imaging or mini-bone marrow harvest * history of sustained chest pain unrelieved by nitrates, occurring 4 or more days before revascularization. * patients who fail to re-perfuse the infarct related coronary artery or have successful stent placement

Keywords: myocardial infarction bone marrow cd34+ stem cells
effectiveness of qufeng shengshi fang on treatment of allergic rhinitis.

Conditions: Rhinitis, Allergic, Perennial

Summary: this is a controlled clinical trials about traditional chinese medicine named qufeng shengshi fang，which consisted of cicada slough，bombyx batryticatus，radix angelicae，radix sileris，honeysuckle flower，forsythia，lithospermum and radix glycyrrhizae，and loratadine on treatment of allergic rhinitis.there are 180 patients with allergic rhinitis recruited from department of allergy and traditional chinese.to carry on statistical analysis of the result of the self and between-group cross-reference by two questionnaires filled before and after treatment.


Eligibility criteria:
inclusion criteria: * meet allergic rhinitis (include allergic rhinitis with asthma) diagnostic criteria at peking union medical college hospital department of allergy; * have allergic rhinitis in episodes. * without antihistamine,local anaesthetic or traditional chinese medicine in last months. * signed the informed consent form. exclusion criteria: * have severe deviation of nasal septum and nasal polyps. * have nasal surgery or a history of cancer(tumor). * have other serious illness or evidence of mental disorders. * female in pregnancy and lactation

Keywords: traditional chinese medicine loratadine questionnaire survey
preoperative guided imagery in patients undergoing urologic surgery

Conditions: Urologic Cancer

Summary: this is a prospective randomized controlled trial of patients undergoing major urologic-oncologic surgery at the university of california, san francisco (ucsf) medical center and the helen diller family comprehensive cancer center. this clinical trial examines the effect of guided meditation before surgery on the levels of anxiety, stress, sleep disturbance, and quality of life among patients scheduled to undergo a major urologic surgery for cancer. a cancer diagnosis and the treatments associated with it can be very stressful for patients, leading to depression, sleep disturbances, and lower quality of life. mind-body practices such as guided meditation have been used for thousands of years to reduce the effects of chronic stress and to improve quality of life. this clinical trial examines the effects of guided meditation on the stress, depression, and quality of life levels of patients undergoing urologic surgery for their cancer.

primary objective: i. to determine the effect of 14 days of preoperative guided visualization meditation on patients' anxiety undergoing major urologic-oncology surgery. secondary objectives: i. to determine the effect of preoperative guided visualization meditation on patients' depression, stress, and quality of life. ii. to examine the difference in hospital consumer assessment of healthcare providers and systems (hcahps) survey question scores between the two study groups. iii. to determine the ability of patient to perform a daily 23 minute meditation. iv. to examine the correlation between depression and emergency department (ed) visits and readmissions post-operations. outline: patients are randomized to 1 of 2 arms. arm 1: patients listen to guided meditation over 23 minutes daily for two weeks before their standard of care surgery. patients also complete surveys over 10-15 minutes at baseline, after 10 days, 1 day before standard of care surgery, the day after discharge, and then 4 weeks after surgery. arm 2: patients complete surveys over 10-15 minutes at baseline, after 10 days, 1 day before standard of care surgery, the day after discharge, and then 4 weeks after surgery.

Eligibility criteria:
inclusion criteria: * greater than or equal to 18 years of age. * patients undergoing radical cystectomy, radical or partial nephrectomy, or radical prostatectomy at the university of california, san francisco (ucsf) medical center and the helen diller family comprehensive cancer center * access to an electronic device that can play mp3 recording and for survey completion * at least a 2 week window from date of surgical booking to the scheduled surgery exclusion criteria: * inability to consent for the study (ie, they have a surrogate decision maker). * non-english speaker (the meditations are only available in english) * patients scheduled for surgery less than 2 weeks away

Keywords: meditation guided imagery urologic-oncology surgery anxiety reduction radical cystectomy radical nephrectomy partial nephrectomy radical prostatectomy
a mobile phone app to promote healthy diet and physical activity in 2.5-year-olds

Conditions: Obesity, Childhood

Summary: childhood obesity is still a major global health issue. the preschool age (2-5 years) has been identified as a critical period to intervene, mobile technology (mhealth) has been successful for weight loss and behavior changes in adults. this proposed randomized controlled trial aims to assess the effectiveness of an 6-month intervention program, the mobile-based intervention to stop obesity in preschoolers (ministop) 2.0 mobile phone app integrated in primary child health care for parents of children aged 2.5 years. the ministop 2.0 app is built on the previous ministop 1.0 app. five hundred children will be recruited at their routine visit at 2.5 years of age and after baseline measures randomized to the intervention or control group. in addition, the investigators will assess acceptability, feasibility and appropriateness of the app by parents and primary child health care nurses.


Eligibility criteria:
inclusion criteria: -children at the routine visit at 2.5-3 years of age at selected primary child health centers in sweden exclusion criteria: * children diagnosed with neurological or endocrine diseases * children who have a parent suffering from a serious physical or psychological disease making the study too demanding for the family * children from families who will not be able to understand the content of the app (i.e. do not speak swedish, english, somali or arabic)
molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors

Conditions: Parathyroid Gland Adenoma; Parathyroid Gland Atypical Adenoma; Parathyroid Gland Carcinoma; Primary Hyperparathyroidism

Summary: this trial studies molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors. studying molecular and immunohistochemical profiling of tumors may help doctors avoid inconsistencies in diagnosis, unnecessary or incomplete surgery, surgical morbidity, psychological stress, and inadequate follow up.

primary objectives: i. to determine the differences in clinical behavior and immunohistochemical (ihc) biomarkers between parathyroid carcinoma (pc), atypical neoplasm (an) and parathyroid adenoma (pa). ii. to determine which potential genes can be used in patients with parathyroid tumors for diagnostic purposes. outline: previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.

Eligibility criteria:
inclusion criteria: * the patient cohort for this study consists of all patients within the prospectively maintained parathyroid database within the department of surgical oncology at the university of texas md anderson cancer center (mdacc) or from collaborating sites, with tissue or blood available from 1968-2015, previously consented for the use of the tissue for research purposes (via protocols lab 08-0034, pa11-0695 and lab03-0320 or the appropriate external mechanism for collaborating sites). * all patients with a known diagnoses of primary hyperparathyroidism (phpt) operated/treated in the department of surgical oncology of mdacc or at a collaborating site. patients that have provided consent for the use of the tissue or blood for research purposes will then be considered for our study (via protocol lab03-0320 and lab 08-0034 or the appropriate external mechanism for collaborating sites). * all consented patients with known diagnoses of phpt with a histopathological diagnosis of: parathyroid carcinoma, atypical parathyroid neoplasm or parathyroid adenoma. there will be no restrictions on age, gender, or ethnicity. * selected patients obtained through outside collaboration who meet the selection criteria for tissue availability and diagnostic suitability for inclusion in the study. exclusion criteria: * patients without tissue available for analysis.